COBAS 4800 BRAF V600 MUTATION TEST
Roche Molecular Systems, Inc. · Decision date Aug 17, 2011
What did the FDA approve?
FDA records P110020 as an original PMA application. The recorded decision is approval, dated Aug 17, 2011.
FDA approval order statement
APPROVAL FOR THE COBAS 4800 BRAF V600 MUTATION TEST. THIS DEVICE IS INDICATED FOR: THE COBAS 4800 BRAF V600 MUTATION TEST IS AN IN VITRO DIAGNOSTIC DEVICE INTENDED FOR THE QUALITATIVE DETECTION OF THE BRAF V600E MUTATION IN DNA EXTRACTED FROM FORMALIN-FIXED, PARAFFIN-EMBEDDED HUMAN MELANOMA TISSUE. THE COBAS 4800 BRAF V600 MUTATION TEST IS A REAL-TIME PCR TEST ON THE COBAS 4800 SYSTEM, AND IS INTENDED TO BE USED AS AN AID IN SELECTING MELANOMA PATIENTS WHOSE TUMORS CARRY THE BRAF V600E MUTATION FOR TREATMENT WITH VEMURAFENIB.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Aug 17, 2011
Regulatory record facts
- Identifier
- P110020
- Regulatory pathway
- Premarket approval application
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- OWD
- Decision code
- APPR
- Decision date
- Aug 17, 2011
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Somatic gene mutation detection system.
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- OWD
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P110020 received
Application receipt date recorded by FDA.
P110020 · FDA decision
APPR
P110020/S045 · Related supplement
cobas BRAF V600 Mutation Test
P110020/S046 · Related supplement
Roche cobas BRAF V600 Mutation Test
Timeline entries are records held by MedtechLedger for P110020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas BRAF V600 Mutation TestP110020/S045 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Roche cobas BRAF V600 Mutation TestP110020/S046 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code OWD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Roche cobas EGFR Mutation Test, v2.0P120019/S045 | Roche | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas KRAS Mutation TestP140023/S034 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
cobas EGFR Mutation Test, v2.0P120019/S044 | Roche | PMA supplement | Oct 27, 2026 | FDA |
cobas KRAS Mutation TestP140023/S033 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas EZH2 Mutation TestP200014/S012 | Roche Molecular System, Inc. | PMA supplement | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Molecular Systems, Inc.
- Headquarters
- Not reported
- Brand website
- roche.com
- FDA applicant address
- 4300 Hacienda Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P110020
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



